Jane Ivanidze, Associate Professor of Radiology at Weill Cornell Medicine, shared on LinkedIn:
“I could not be more excited to share that our multi-institutional team has received ~$3.5 million in NIH/NCI funding to investigate dual-tracer [F18]FMISO/[F18]FLT PET in glioblastoma.
This is my first R01 as a Multi Principal Investigator, reflecting years of collaboration, late-night writing, and many (many!) grant submissions.
I am deeply grateful to my fellow MPIs, Sadek Nehmeh and Ramon Barajas Jr, for their partnership, as well as to our amazing collaborators across physics, neuro oncology, neuropathology, and neurosurgery.
I also want to acknowledge my mentors, my wonderful trainees and colleagues, and the supportive research environments at Weill Cornell Medicine and Oregon Health and Science University that have helped make this work possible.
And of course this would not have happened without the support of Matt and our boys.
With IRB approval now in place, we anticipate beginning patient enrollment in the coming weeks. Can’t wait to get to work toward improving care for patients with glioblastoma.”
To which, Ramon Barajas Jr, Professor of Radiology at Oregon Health and Science University, added:
“It has been an almost 10 year adventure with Jana Ivanidze to advance our understanding of how hypoxia impacts our patients fighting glioblastoma.
Now paired with Sadek Nehmeh, to make this collaborative Oregon Health and Science University, OHSU Knight Cancer Institute, OHSU Diagnostic Radiology, Cornell RadioLigand Lab study happen!
Can’t wait for the next chapter to unfold.”
You can also read: FDA Approves Floretyrosine F 18 for PET Imaging in Glioma
